Histology
Squamous Cell Carcinoma
CI-CAN-00001550SCCExplore in graph →
976 active trials9 approved drugs78 evidence items
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001550SCCExplore in graph →
Clinical trials
2,930 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (402)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03833167 | Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630) | terminated | Phase 3 | 450 | Merck Sharp & Dohme LLCINDUSTRY | 24 | Sep 28, 2026 | clinicaltrials |
| NCT06790966 | Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma(VERSATILE-003) | terminated | Phase 3 | 12 | PDS Biotechnology Corp.INDUSTRY | 1 |
| Sep 2, 2026 |
| clinicaltrials |
| NCT04949256 | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014). | terminated | Phase 3 | 863 | Merck Sharp & Dohme LLCINDUSTRY | 25 | Aug 21, 2026 | clinicaltrials |
| NCT06295809 | A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)(INTerpath-007) | terminated | Phase 2 / Phase 3 | 46 | Merck Sharp & Dohme LLCINDUSTRY | 20 | May 8, 2026 | clinicaltrials |
| NCT04459715 | A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX) | terminated | Phase 3 | 730 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 26 | Oct 8, 2025 | clinicaltrials |
| NCT04458909 | Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer | terminated | Phase 3 | 15 | National Cancer Institute (NCI)NIH | 4 | Oct 3, 2025 | clinicaltrials |
| NCT05930938 | Study Comparing RT With Cetuximab + Xevinapant to RT With Cetuximab-placebo in Patients With Head and Neck Cancer(XXL_2022-01) | terminated | Phase 3 | 19 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 1 | May 9, 2025 | clinicaltrials |
| NCT00448240 | Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer | terminated | Phase 2 / Phase 3 | 6 | Henry Ford Health SystemOTHER | 0 | Mar 18, 2025 | clinicaltrials |
| NCT03452137 | A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck(IMvoke010) | terminated | Phase 3 | 406 | Hoffmann-La RocheINDUSTRY | 23 | Oct 9, 2024 | clinicaltrials |
| NCT00946712 | S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer | terminated | Phase 3 | 1,333 | SWOG Cancer Research NetworkNETWORK | 2 | May 23, 2023 | clinicaltrials |
| NCT02236936 | Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck(AGMT_HNO_PN) | terminated | Phase 3 | 8 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | May 1, 2020 | clinicaltrials |
| NCT02926638 | Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches | terminated | Phase 2 / Phase 3 | 9 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 19, 2020 | clinicaltrials |
| NCT00262821 | Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer | terminated | Phase 3 | 402 | National Cancer Institute (NCI)NIH | 2 | Jul 23, 2019 | clinicaltrials |
| NCT01627379 | Cisplatin and 5-FU +/- Panitumumab for Patients With Nonresectable,Advanced or Metastatic Esophageal Squamous Cell Cancer(POWER) | terminated | Phase 3 | 300 | AIO-Studien-gGmbHOTHER | 1 | Mar 2, 2018 | clinicaltrials |
| NCT01740375 | Role of Esophagectomy in Complete Responders to CCRT(ESOPRESSO) | terminated | Phase 3 | 486 | Asan Medical CenterOTHER | 1 | Aug 29, 2017 | clinicaltrials |
| NCT00190554 | A Trial of Chemotherapy Before and After Surgery for Stage II,III Esophageal Squamous Cell Carcinoma | terminated | Phase 3 | 330 | Japan Clinical Oncology GroupOTHER | 1 | Sep 22, 2016 | clinicaltrials |
| NCT01161498 | Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer | terminated | Phase 3 | 5 | BioVex LimitedINDUSTRY | 2 | Feb 8, 2016 | clinicaltrials |
| NCT01532453 | Prevention of UV-induced Carcinogenic Skin Alterations in Immunosuppressed Solid Organ Transplanted Patients | terminated | Phase 3 | 244 | Spirig Pharma Ltd.INDUSTRY | 9 | Jan 8, 2016 | clinicaltrials |
| NCT00412776 | Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck Cancer | terminated | Phase 2 / Phase 3 | 165 | Sesen Bio, Inc.INDUSTRY | 18 | Dec 23, 2015 | clinicaltrials |
| NCT00911326 | Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma | terminated | Phase 3 | 101 | Navidea BiopharmaceuticalsINDUSTRY | 1 | Aug 8, 2014 | clinicaltrials |
| NCT00596830 | Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology | terminated | Phase 3 | 681 | PfizerINDUSTRY | 26 | Jan 13, 2014 | clinicaltrials |
| NCT00673049 | Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer(NSCLC) | terminated | Phase 3 | 583 | PfizerINDUSTRY | 27 | Jul 24, 2013 | clinicaltrials |
| NCT01363466 | Evaluation of Hysterectomy After Chemoradiation Therapy for Stage IB2/II Cervical Cancer | terminated | Phase 3 | 61 | UNICANCEROTHER | 1 | Jun 1, 2011 | clinicaltrials |
| NCT00559351 | RCT on the Combined Modality Treatment of Squamous Cell Carcinoma of the Esophagus | terminated | Phase 3 | 84 | Ministry of Scientific Research and Information Technology, PolandOTHER_GOV | 1 | Nov 16, 2007 | clinicaltrials |
Data updated 2 days agoSource updated Sep 28, 2026source: clinicaltrials